Compare Credo Technology Group Holding Ltd (CRDO) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs GSK plc — how do they compare? Credo Technology Group Holding Ltd trades at $222.24 (market cap $44.04B), while GSK plc trades at $51.6 (market cap $101.55B). The key difference: GSK plc is far larger — about 2.3× Credo Technology Group Holding Ltd's market cap, and GSK plc pays a 3.5% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals.
| CRDO | GSK | |
|---|---|---|
Market Cap | $44.04B | $101.55B |
Sector | Technology | Health |
52-Week High | $302.52 | $61.18 |
52-Week Low | $87.81 | $36.20 |
Enterprise Value | $42.62B | $122.16B |
Dividend Yield | — | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $236.88, down 8.11% over the past 24 hours, with technical indicators showing neutral momentum near key support at $231. The company demonstrates exceptional fundamental strength with 35.37% net income margin and 34.41% ROE, though valuation metrics appear elevated with a P/E of 94.1. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.16 surpassing the $1.02 forecast.
The outlook remains positive with analyst consensus at $273.33 target (15.4% upside) and 87% buy ratings. Key risks include high valuation multiples and dependence on AI infrastructure demand growth. The company's strong cash flow generation and triple-digit revenue growth projections for 2026 support continued upside potential despite near-term volatility.
GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.
GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
